These results are consistent with other AMPK activators such AICAR [37], berberine [23], resveratrol [38] and glabridin [24], which showed similar anti-obesity effects, associated with decreased expression of hepatic lipogenic enzymes and reduced lipid synthesis in vivo. The gene discussed is PRKAA1; the disease is obesity disorder.